Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

HAVN Life Sciences Inc. (C:HAVN)

Business Focus: Biotechnology & Medical Research

Oct 08, 2021 06:00 pm ET
HAVN Life Receives Extension of Six Months to Hold its Annual General Meeting from the Registrar of Companies, British Columbia
VANCOUVER, BC , Oct. 8, 2021 /CNW/ – HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life") announces that it has been granted an extension of six months by the Registrar of Companies, to hold its first Annual General Meeting under section 182(4) of the Business Corporations Act (British Columbia). The six months extension is from October 8, 2021, to April 8, 2022.
Oct 07, 2021 08:00 am ET
HAVN Life Files Final Base Shelf Prospectus
VANCOUVER, BC, Oct. 7, 2021 /CNW/ - HAVN Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "HAVN Life") is pleased to announce that it has filed its final short form base shelf prospectus (the "Final Shelf Prospectus") with the securities commissions in each of the provinces and territories of Canada and received a final receipt in respect thereof.
Oct 01, 2021 09:33 pm ET
HAVN Life Provides an Update on its Operations
VANCOUVER, BC, Oct. 1, 2021 /CNW/ - Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF) (FSE: 5NP) (the "Company" or "Havn Life") provides an update on its operations.
Sep 29, 2021 11:41 am ET
HAVN Life Acquires Bennett's Choice Patented Brain Health and Recovery Formulations
Along with adding new formulations to the Company's natural health product portfolio, founder Matthew Bennett to join HAVN Life as Director of Education
Sep 23, 2021 09:30 am ET
HAVN Life Announces Supply and Distribution MOU with Mycrodose Therapeutics
The partnership is a integral step in the The Company's path to market in the U.S., achieving one of its most important milestones to-date
Sep 21, 2021 08:00 am ET
HAVN Life Announces Distribution Deal with Horizon Grocery + Wellness
VANCOUVER, BC / ACCESSWIRE / September 21, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychedelic compounds for the creation of active pharmaceutical ingredients that support brain health and enhance the capabilities of the mind, is pleased to announce their partnership with Horizon Grocery + Wellness, Western Canada's leading distributor of organic and natural foods, natural personal care items, and nu
Aug 25, 2021 08:00 am ET
HAVN Life Signs Agreement to Supply Psilocybin for Mycotopia Therapies
The partnership will further industry growth for naturally derived psilocybin
Aug 25, 2021 08:00 am ET
Mycotopia Therapies Signs Agreement With Havn Life Sciences For Purchase of Psilocybin SPP
Mycotopia Therapies, Inc. (OTC Pink: TPIA) (the “Company”), a company focused on psychedelic therapies, announced today it has entered into a Psilocybin Supply Agreement with Havn Life Sciences (CSE: HAVN) (OTC Pink: HAVLF). The terms of the...
Aug 11, 2021 07:00 am ET
Havn Life Sciences TO Present at Q3 Investor Summit Virtual Conference
Vancouver, British Columbia--(Newsfile Corp. - August 11, 2021) - Havn Life Sciences Inc. (CSE: HAVN) (OTC Pink: HAVLF) (FSE: 5NP) (the "Company" or "Havn Life"), a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind today announced that it will be presenting at the upcoming Q3 Investor Summit Virtual Conference. Details of the presentation are below.
Aug 03, 2021 08:00 am ET
HAVN Life Harvests First Crop of Psilocybin Mushrooms at its Jamaica Facility
HAVN Life will export to Delic Labs in Canada for quality control and testing. This makes HAVN Life the first in the Caribbean Community and Common Market to export psilocybin.
Jul 29, 2021 08:00 am ET
HAVN Life Natural Health Products Now Available on Amazon.ca
With FBA designation, the Company continues to grow its retail footprint by partnering with the world's largest ecommerce site
Jul 27, 2021 08:00 am ET
HAVN Life Signs Agreement to Enable Export of Psilocybin into Canada, the US and Europe
The Agreement with P.A. Benjamin Manufacturing Company whom operates a GMP compliant facility in Jamaica
Jul 08, 2021 08:00 am ET
HAVN Life Signs Exclusive Supply Agreement With Cube Psytech
The Company will supply naturally-derived psilocybin for the development of psilocybin microdosing health products
Jun 29, 2021 08:00 am ET
Allied Corp Signs Psilocybin Manufacturing Agreement To Produce Psilonex™ RX For What We Believe To Be The Largest Known Psilocybin Patient Cohort In The World
Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) an international medical company focused on creating and providing health solutions to address today’s medical mental health issues is pleased to announce the signing of a supply and...
Jun 29, 2021 08:00 am ET
HAVN Life Sciences Signs Finished Goods Supply Agreement with Allied Health
The Agreement will utilize HAVN Life's fully integrated supply chain model, from the growing of psilocybin through to extraction, compounding, and encapsulation
Jun 08, 2021 08:00 am ET
HAVN Life Announces Retail Partnership with Grocer, Choices Markets
Newly-launched line of natural health products to be available at all locations later this month
Jun 03, 2021 08:00 am ET
HAVN Life Launches New Line of Natural Health Products
Seven New Formulations That Support Brain Health and Immune Function Will Be Available Online and at Select Retail Locations Starting June 3
Jun 02, 2021 08:00 am ET
HAVN Life Completes Acquisition of Clinical Stage IP for Development of Cluster Headache Drug
The Company will seek Orphan Drug Designation to significantly reduce time to market
May 19, 2021 08:00 am ET
HAVN Life Secures Production & Supply Agreement to Expand Retail Product Offerings
Natural Health Products Will Be Manufactured and Packaged at the Company's New Facility
May 17, 2021 08:00 am ET
HAVN Life Enters into Agreement to Acquire Clinical Stage IP for Development of LSD-Derived API for Cluster Headaches
HAVN Life works towards substantiating a patent application and preclinical work
May 14, 2021 08:00 am ET
Havn Life CEO Tim Moore to Appear at Upcoming Q2 Investor SummitHavn Life CEO Tim Moore to Appear at Upcoming Q2 Investor Summit
Havn Life will join 80+ other small cap and micro-cap companies at leading event for investors
May 13, 2021 08:00 am ET
Havn Life Signs Exclusive Supply Agreement with ATMA Journey Centers
Havn Life to supply naturally-derived psilocybin to ATMA Journey Centers in Alberta and Nicoya Peninsula, Costa Rica
May 11, 2021 08:00 am ET
Havn Life Develops New Method for Rapid Psilocybin Testing
Havn Life has completed its analytical work under its Health Canada Section 56 exemption
May 04, 2021 08:00 am ET
Havn Labs Jamaica Facility Now Fully Operational
The Company has started production of its first grow with local partner Hypha Wellness
Apr 08, 2021 08:00 am ET
Havn Life Completes Acquisition of Strategic Manufacturing & Packaging Facility for its Retail Division
The Facility acquisition positions Havn Life to quickly expand its product portfolio and reach additional NHP categories.
Mar 25, 2021 08:00 am ET
Havn Life Sciences Signs LOI to Research and Develop Medical Psilocybin with Jamaican Company Hypha Wellness
Havn Life believes operations can advance its business plan and potentially accelerate production of naturally-derived psilocybin for global medical research.
Mar 19, 2021 08:00 am ET
Havn Life CEO to Present at Zooming with LD, a Leading Platform for Microcap Companies
CEO Tim Moore will appear on Tuesday, March 24th at 8:00 AM PT/ 11:00 AM ET
Mar 16, 2021 08:00 am ET
Havn Life Introduces Industry Leader Jenna Pozar as Chief Operating Officer
Pozar will lead sales, marketing, e-commerce and logistics for Havn Retail
Feb 26, 2021 08:00 am ET
Havn Life Sciences to Host Investor Webcast on March 3, 2021
Attendees will have the opportunity to get the latest updates and participate in Q & A with Havn Life's CEO Tim Moore
Feb 22, 2021 08:00 am ET
Havn Life Announces DTC Eligibility of Its Common Shares in the United States
VANCOUVER, BC / ACCESSWIRE / February 22, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce today that its common shares are now elig
Feb 17, 2021 08:00 am ET
Havn Life Announces Changes to Board Composition and Departure of Ms. Rasode
VANCOUVER, BC / ACCESSWIRE / February 17, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life"), announces the departure of Ms. Barinder Rasode as President and as a director of the Company, effective immediately.
Feb 02, 2021 08:00 am ET
Havn Life Announces Strategic Clinical Trial Partnership with HealthTech Connex Inc.
Havn Life to supply psychedelic compounds for clinical trials launched by neuroscience and technology leader HealthTech Connex
Jan 26, 2021 08:00 am ET
Havn Life Sciences Enters Definitive Agreement to Acquire Strategic Manufacturing & Packaging Facility for its Retail Division
The acquisition is intended to vertically integrate the Company's retail manufacturing capabilities to support the growth of its nutraceutical division and deliver unique products to consumers
Jan 22, 2021 08:00 am ET
Havn Life Sciences Announces Inclusion in First Psychedelic Exchange Traded Fund
VANCOUVER, BC / ACCESSWIRE / January 22, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it will be included in the First Psychedelics Exchange Traded Fund ("ETF"). The ETF will begin traded on the
Jan 18, 2021 08:00 am ET
Havn Life to Support Canadian Counterpart of Veterans' Organization, Heroic Hearts
Havn Life to grow its partnership with the US-based veterans' organization by funding and supporting the launch of its Canadian counterpart.
Jan 07, 2021 09:00 am ET
Havn Life Sciences announces closing of C$11.5 million Bought Deal Financing
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Dec 22, 2020 08:00 am ET
Havn Life Sciences and Nesters Market, a Leading Canadian Retailer of Natural Health and Wellness Products, Announce an Authorized Products Listing
Nesters Market retail chain, will list and promote the full range of Havn Life's natural health supplements across its stores in British Columbia in Q1 2021
Dec 18, 2020 06:55 pm ET
Havn Life Sciences Files Preliminary Prospectus in Connection with Bought Deal Equity Financing
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
Dec 17, 2020 08:00 am ET
Havn Life Sciences Provides Update on Retail Strategy and Product Development
Havn Retail is on track for its Q1 2021 launch of its initial line of natural health supplements.
Dec 16, 2020 08:00 am ET
Havn Life Sciences Hits Major Milestone with Research Partner, Complex Biotech Discovery Ventures
Havn Research signs contract with CBDV, located at The University of British Columbia's Vancouver campus, to begin Health Canada approved research to analyze psilocybin under Havn Life's Section 56 exemption.
Dec 15, 2020 10:06 am ET
IIROC Trade Resumption - HAVN
VANCOUVER, BC, Dec. 15, 2020 /CNW/ - Trading resumes in:
Dec 15, 2020 10:01 am ET
Havn Life Sciences announces increase in Bought Deal Financing to $10 Million
Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that it has entered into an amended agreement with Eight Capital, pursuant to which Eight Capital has now agreed to buy, on a bought deal basis,...
Dec 15, 2020 08:35 am ET
IIROC Trading Halt - HAVN
VANCOUVER, BC, Dec. 15, 2020 /CNW/ - The following issues have been halted by IIROC:
Dec 15, 2020 07:30 am ET
Havn Life Sciences announces $5 million Bought Deal Financing
Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”) is pleased to announce that it has entered into an agreement with Eight Capital, pursuant to which Eight Capital has agreed to buy, on a bought deal basis, 4,673,000...
Dec 14, 2020 08:00 am ET
Havn Life Sciences Undertakes One of the First Preclinical Studies on Psilocybin and the Immune System
This is one of the first studies to examine how psilocybin affects the immune system and is a required step to file an application with the Food and Drug Administration (FDA), for a Phase 1 clinical study in humans
Dec 08, 2020 08:00 am ET
Havn Life Sciences to Supply Psychedelic Compounds to Clinical Studies Focused on Veterans and PTSD
Havn Life will collaborate on future clinical studies with Heroic Hearts Project to investigate effects of low-dosage psychoactive compounds on veterans the post-traumatic stress disorder (PTSD).
Dec 03, 2020 08:00 am ET
Havn Life Sciences Partners With Veterans Mental Health Non-Profit, Westwood Institute
Westwood Institute Founder, Dr. Marvin Westwood Will Work With Havn Life's Research Team to Develop Best Practices for Combining Therapy and Psychedelic Interventions for Veterans
Dec 01, 2020 08:00 am ET
Havn Life Attracts International Drug Science and Policy Expert, Joins UK Policy Reform Group
VANCOUVER, BC / ACCESSWIRE / December 1, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce it has become a voting member of the Conservative Drug Policy Reform Group (CDPRG).
Nov 24, 2020 08:00 am ET
Havn Life Sciences Announces $5.46 Million Warrant Exercise
VANCOUVER, BC / ACCESSWIRE / November 24, 2020 / Havn Life Sciences Inc. (CNSX:HAVN)(FSE:5NP) (the "Company" or "Havn Life") is pleased to announce that 10,927,856 common share purchase warrants ("Warrants") have been exercised ("Exercise"), resulting in proceeds to the Company of $5.46 million. The Warrants had originally been issued by the Company pursuant to a private placement that closed on June 5, 20
Nov 18, 2020 08:00 am ET
Havn Life announces Voluntary Escrow of 6,300,000 Shares
The Voluntary Escrow serves further validates investors belief and support of Havn Life's business plan and future growth strategy
Nov 11, 2020 08:00 am ET
Havn Life Announces Launch of a Range of Natural Health Products
The 7 initial formulations are designed to support and enhance memory and brain function, the immune system, energy levels, and overall wellness while reducing the negative impacts of stress.
Oct 30, 2020 08:00 am ET
Havn Life Sciences to Support the First Modern Psilocybin Depression Study in Germany With MIND Foundation
The research will be led by Prof. Dr. Gerhard Gründer, the only confirmed scientist developing a study to work with psychedelics in Germany since the 1970s
Oct 26, 2020 08:00 am ET
Havn Life Sciences Earns Health Canada Approval for Natural Health Product Formulations
The initial six approved formulations were developed to enhance human performance and cognitive health
Oct 20, 2020 07:00 am ET
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has signed a...
Oct 19, 2020 08:00 am ET
Havn Life Sciences Announces Appointment of Dennis Staudt to the Board of Directors & Senior Management Reorganization
VANCOUVER, BC / ACCESSWIRE / October 19, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), is pleased to announce that Mr. Dennis Staudt has joined the Company's Board of Directors. Mr. Staudt has over 35 years' experience providing sophisticated business advice, having spent most of his career with PricewaterhouseCoopers LLP ("PwC"), including 22 years as a partner in PwC's Audit and A
Oct 13, 2020 08:00 am ET
Havn Life Applies for Licence to Produce and Sell Psilocybin
The Controlled Drugs and Substances Dealer's Licence will allow Havn Life to supply naturally-derived psilocybin globally to universities, clinical researchers and companies
Oct 05, 2020 08:00 am ET
Havn Life Sciences Announces Appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors, Respectively, and the Acceleration of Warrants
VANCOUVER, BC / ACCESSWIRE / October 5, 2020 / Havn Life Sciences Inc. (CSE:HAVN)(FSE:5NP) (the "Company" or "Havn Life") is pleased to announce that Mr. Vic Neufeld has been appointed as the Chairman of the Board of Directors of the Company (the "Board"). Mr. Neufeld brings a wealth of knowledge and experience in the Natural Health Food industry, having served as the Chief Executive Officer of Jamieson Laboratories ("Jamieson"), Canada
Oct 01, 2020 08:00 am ET
Havn Life joins UK Psychedelics Working Group with Leading International Scientists
The Working Group Consists of Over 35 Academics, Researchers, and Policy Specialists From Four Countries
Sep 29, 2020 08:35 pm ET
Havn Life Sciences Inc. Reports Q1 Financial Statements
VANCOUVER, BC / ACCESSWIRE / September 29, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (FSE:5NP) (the "Company" or "Havn Life"), is pleased to announce Its financial results for the three month period ended July 31, 2020. Please note that all references to currency are in CDN dollars.
Sep 23, 2020 03:00 am ET
Havn Life Sciences Submits Range of Natural Health Products to Health Canada
Havn Retail, a core pillar of Havn Life continues to reach milestones as the company works towards its launch of a line of retail products
Sep 16, 2020 08:00 am ET
Havn Life Sciences Announces Listing Approval on the Frankfurt Stock Exchange
Havn Life is now cross-listed and trades on both the CSE & FSE
Sep 10, 2020 08:00 am ET
Havn Life Sciences Granted Section 56 Exemption to Begin Scientific Work With Psilocybin
Havn Life will develop methods for safe, standardized, quality- controlled production of medical compounds extracted from the Psilocybe spp. mushroom
Sep 08, 2020 08:00 am ET
Psychedelics Company Havn Life Announces Commencement of Public Trading on the CSE
Havn Life Sciences will trade on the CSE under the Ticker Symbol HAVN
Sep 04, 2020 05:03 pm ET
CSE Bulletin: New Listing - HAVN Life Sciences Inc. (HAVN)
Toronto, Ontario--(Newsfile Corp. - le 4 septembre/September 2020)  - The common shares of HAVN Life Sciences Inc. have been approved for listing on the CSE.
Sep 04, 2020 04:15 pm ET
Havn Life Sciences Announces Completion of Acquisition Transaction
VANCOUVER, BC / ACCESSWIRE / September 4, 2020 / Havn Life Sciences Inc. (CSE:HAVN) (the "Company" or "Havn Life"), is pleased to announce that it has successfully completed its acquisition of HAVN Research Inc. ("HAVN Research"), acquiring 100% of the outstanding shares of HAVN Research (the "Acquisition Transaction"). HAVN Research is a biotechnology company engaged in the business of the research and development of psychopharmacological products, including the formulation of standardized psychoactive compounds derived from fungi.